Rhumbline Advisers Increases Stake in Ventyx Biosciences Rhumbline Advisers expanded its holdings in Ventyx Biosciences by 44.4% during Q4 2024, acquiring an additional 40,813 shares. The firm now owns 132,825 shares valued at $291,000. Despite institutional interest, Ventyx stock has faced significant challenges, including a 3.9% drop recently, as it struggles with market volatility.12